纳米医学
纳米颗粒
生物物理学
纳米技术
化学
肽
癌细胞
转铁蛋白
胶体金
材料科学
圆二色性
纳米毒理学
纳米生物技术
纤维连接蛋白
免疫系统
PLGA公司
支架蛋白
动态光散射
人血清白蛋白
表面改性
基因传递
蛋白质组学
蛋白质吸附
肿瘤微环境
脚手架
细胞生物学
蛋白质-蛋白质相互作用
细胞
转铁蛋白受体
作者
Tanveer Shaikh,Dhanush Lakmal Yapa Amarasekara,Kenneth Hulugalla,Veeresh B. Toragall,Ryan J. Garrigues,Railey Mayatt,Thomas A. Werfel,Tonya N. Zeczycki,Nicholas C. Fitzkee
出处
期刊:
[American Chemical Society]
日期:2026-03-20
卷期号:1 (5): 1290-1309
被引量:4
标识
DOI:10.1021/acsnanomed.5c00203
摘要
Abstract Nanoparticle delivery to tumors remains inefficient, with current nanomedicines achieving only 0.7% injected dose per gram (ID/g) of tumor tissue due to uncontrolled protein corona formation that redirects nanoparticles away from target sites. We engineered biomimetic protein coronas to control nanoparticle-protein interactions and enhance tumor targeting. Competitive binding studies using NMR spectroscopy revealed that transferrin (Tf) and fibronectin (Fn) outcompete albumin (BSA) and immunoglobulin G (IgG) for 15 nm gold nanoparticle surfaces, establishing a binding hierarchy that enables predictable corona composition. Pre-coating nanoparticles with a four-protein combination (BSA+Tf+Fn+IgG) created coronas that selectively enhanced cancer cell uptake while reducing macrophage recognition in vitro. When administered to tumor-bearing mice, these engineered coronas achieved 13 ppm/g tumor accumulation—equivalent to 4% ID/g—representing 6.5-fold improvement over bare nanoparticles and 2.6-fold improvement over PEGylated formulations. Proteomics analysis of secondary coronas formed in human serum revealed that engineered nanoparticles selectively recruit transport and adhesion proteins while limiting immune recognition signatures. The pre-formed coronas maintained targeting protein retention and reduced complement binding compared to controls. Circular dichroism confirmed minimal protein structural perturbation, preserving receptor-binding functionality for active targeting. The strategy harnesses natural protein adsorption processes to create “smart” biological interfaces that simultaneously evade immune clearance and promote tumor cell recognition through multiple receptor pathways. This approach demonstrates the feasibility of treating the coron as a programmable interface, addressing delivery limitations that have hindered clinical translation of cancer nanomedicines. For Table of Contents Only
科研通智能强力驱动
Strongly Powered by AbleSci AI